DnB Asset Management
BBIO icon

DnB Asset Management’s BridgeBio Pharma BBIO Stock Holding History

DnB Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25M Buy
16,841
+2,390
+17% +$173K ﹤0.01% 624
2025
Q4 		$1.11M Buy
14,451
+4,028
+39% +$264K ﹤0.01% 630
2025
Q3 		$541K Buy
+10,423
New +$508K ﹤0.01% 670

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DnB Asset Management's BBIO Position: Q1 2026 in Review

DnB Asset Management increased its BridgeBio Pharma (BBIO) stake by 17% in Q1 2026, buying an estimated $173K and bringing the position to 16,841 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #624.

DnB Asset Management first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • DnB Asset Management held 16,841 shares of BridgeBio Pharma worth $1.25M as of Q1 2026.
  • DnB Asset Management bought 2,390 BridgeBio Pharma shares in Q1 2026, an estimated $173K.
  • BridgeBio Pharma made up ﹤0.01% of DnB Asset Management's portfolio in Q1 2026, its #624 holding.
  • DnB Asset Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.